f9c74189-6bdc-49b9-b984-917ffe2b097d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 80
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- MTORC1_SIGNALING+0.470
- G2M_CHECKPOINT+0.460
- MYC_TARGETS_V1+0.450
- TNFA_SIGNALING_VIA_NFKB+0.410
- ANDROGEN_RESPONSE+0.400
- CHOLESTEROL_HOMEOSTASIS+0.380
- FATTY_ACID_METABOLISM+0.370
- OXIDATIVE_PHOSPHORYLATION+0.360
- PANCREAS_BETA_CELLS+0.350
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.410
- MYOGENESIS-0.310
- HEDGEHOG_SIGNALING-0.220
- KRAS_SIGNALING_DN-0.160
- COAGULATION-0.090
- APICAL_JUNCTION-0.080
- APICAL_SURFACE-0.080
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.060
- NOTCH_SIGNALING+0.030
- BILE_ACID_METABOLISM+0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_2EN3X6HB | high-grade glioma | — | 0.891 |
| 2 | SRR6013490 | — | cohortA4 | 0.883 |
| 3 | DRR168585 | — | — | 0.880 |
| 4 | BS_1A6MQ9ZA | high-grade glioma | — | 0.865 |
| 5 | SRR5903550 | — | cohortA4 | 0.852 |
| 6 | SJEPD030391_D1.RNA-Seq | EPN | Supratentorial EPN | 0.846 |
| 7 | BS_SHJA4MR0 | high-grade glioma | — | 0.840 |
| 8 | E97A62A3-E4D3-435C-9165-C0075358578E | — | — | 0.836 |
| 9 | 27dfc12e-4ed1-4d98-b6af-d4e9cbb96779 | — | — | 0.835 |
| 10 | R328 | — | — | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.380 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |